COYA THERAPEUTICS
Coya Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease. The company’s proprietary CTreg (cryopreservation for Tregs) system is the first in the industry to create an ‘off the shelf’ approach to Treg cell therapy allowing for serial infusions. Through our patented TAI (Tregs Against Inflammation) and EAITM (Exosomes Against Inflammation) platforms, Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Parkinson’s, Alzheimer’s, FTD and autoimmune diseases.
COYA THERAPEUTICS
Industry:
Biopharma Biotechnology Life Science
Founded:
2020-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.coyatherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
1(800) 587-8570
Email Addresses:
[email protected]
Total Funding:
20.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Font Awesome Apache Global Site Tag
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Employees Featured
Founder
Investors List
Allele Capital Partners
Allele Capital Partners investment in Series A - Coya Therapeutics
Key Employee Changes
Official Site Inspections
http://www.coyatherapeutics.com Semrush global rank: 2.71 M Semrush visits lastest month: 6.1 K
- Host name: 16.110.212.35.bc.googleusercontent.com
- IP address: 35.212.110.16
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Coya Therapeutics"
Clinical-Stage Biotech Developing Treg-based Therapies - Coya …
The organization provides resources to help ease the burden on patients and families facing these challenges. Daniel holds an MBA from Rice University and a B.S. in Mechanical Engineering …See details»
Houston biotech company developing multiple Treg-based therapies
We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. We are currently developing our multi-modality …See details»
Coya Therapeutics - Governance - Board of Directors
Howard H. Berman, Ph.D., has served as Chairman of the board of directors of Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, since he co …See details»
Coya Therapeutics, Inc. | LinkedIn
Coya Therapeutics, Inc. | 3,885 followers on LinkedIn. Unleashing the power of Tregs to tackle neurodegenerative and autoimmune diseases. | Headquartered in Houston, TX, Coya Therapeutics, Inc ...See details»
Coya Therapeutics - Investor Relations
Mar 18, 2025 [email protected]. Email Alerts. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting …See details»
Coya Therapeutics - Coya Therapeutics Provides a Corporate …
Mar 18, 2025 Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell …See details»
Coya Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 1(800) 587-8570 Coya Therapeutics is a clinical-stage biotechnology company developing multiple first-in-class and best-in-class …See details»
Coya Therapeutics Secures $10 Million Financing to Advance …
Coya Therapeutics’ clinical and biomarker data continue to demonstrate regulatory T cells (Tregs) ability to meaningfully dampen both systemic and neuroinflammation, thereby restoring the …See details»
Coya Therapeutics (COYA) Company Profile & Description - Stock …
Dec 29, 2022 5850 San Felipe St., Suite 500 Houston, Texas 77057 United StatesSee details»
Houston Biotech Company Targeting Treg Dysfunction
Clinical-stage Coya Therapeutics modulates Tregs through Treg modifying biologics, allogenic Treg-derived exosomes, & autologous Treg cell therapySee details»
Company Information - RocketReach
Coya Therapeutics, Inc. employs 13 employees. The Coya Therapeutics, Inc. management team includes Howard Berman (Founder and Chief Executive Officer), Michelle Frazier (Senior Vice …See details»
Coya Therapeutics, Inc. Information - RocketReach
Coyatherapeutics.com; View Similar People. Related Companies Powers Brown Architecture. 129 $21.1m Alchemy Technology Group, LLC. 156 $14.6m Intuitive Machines. 351 $17.2m Main …See details»
Coya Therapeutics - Governance - Executive Management
[email protected]. Email Alerts. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your …See details»
Coya Therapeutics - Coya Therapeutics (“Coya”) Appoints Industry …
Jul 5, 2023 [email protected]. Hayden IR: James Carbonara (646)-755-7412 [email protected]. Media Contact Anna Marie Imbordino [email protected] …See details»
Coya Therapeutics™ Completes Merger with Nicoya Health Inc.
Feb 3, 2021 For more information, please visit www.coyatherapeutics.com Investor Contact Media Contact: Daniel Ferry 617-430-7576 [email protected]: Joleen Schultz 760 …See details»
Coya Therapeutics - VentureRadar
"Coya is developing disruptive, first in class, autologous regulatory T-cell (Treg) and allogeneic exosome therapies - leveraging the seminal discoveries from the laboratory of Stanley Appel …See details»
Coya Therapeutics - Coya Therapeutics CEO Dr. Arun …
Nov 19, 2024 [email protected] 212-655-0924 Source: Coya Therapeutics, Inc. View All News. We are a clinical-stage biotechnology company focused on developing …See details»
Coya Therapeutics - Craft
Oct 29, 2024 Coya Therapeutics has 2 employees at their 1 location and $6 m in annual revenue in FY 2023. See insights on Coya Therapeutics including office locations, …See details»
Coya Therapeutics - Coya Therapeutics, Inc. Announces Pricing of …
Dec 29, 2022 Coya Therapeutics, Inc. (Coya or the Company) (Nasdaq: COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory …See details»
Coya Therapeutics Announces Successful Completion of Pre-IND …
For more information, please visit www.coyatherapeutics.com. Investor Contact Daniel Ferry 617-430-7576 [email protected]. Media Contact Jessica Starman …See details»